Eli Lilly and Company / Profluent Bio

Genetic Diseases Addressable by Site-Specific Recombinase Gene Editing (Platform)

$5.5B US Market · ~95% Profluent OpenCRISPR-1 reduction in unintended modifications vs SpCas9

Disease Overview

Profluent's AI-designed site-specific recombinases address a class of genetic diseases that current gene editing modalities (CRISPR-Cas9 nuclease, base editing, prime editing) cannot efficiently treat - particularly diseases caused by large or heterogeneous mutations across patient populations, where single-base or short-stretch edits are insufficient. Recombinases are enzymes that recognize specific DNA sequences and catalyze precise insertion, deletion, inversion, or translocation of large DNA segments (kilobases) at defined genomic locations. Naturally occurring recombinases (Cre, Flp, Bxb1) have very limited target sequences, restricting their therapeutic utility. AI-designed recombinases - which Profluent CEO Ali Madani has called the 'holy grail' of genetic medicine - aim to enable durable, single-treatment correction of monogenic disorders with heterogeneous mutational spectra (Duchenne muscular dystrophy, cystic fibrosis, hemophilia, sickle cell disease, lysosomal storage disorders, and certain cardiomyopathies and ophthalmologic diseases) by inserting full healthy gene copies. The platform is differentiated from CRISPR/Cas-based editing by avoiding double-strand breaks, reducing off-target activity (Profluent's OpenCRISPR-1 reportedly cut unintended modifications by ~95% versus SpCas9), and unlocking diseases requiring large-payload insertion. Specific lead indications were not disclosed in the announcement.

Competitive Landscape

The genetic medicine landscape is increasingly stratified by editing modality. CRISPR-Cas9 nuclease leaders (Vertex/CRISPR Therapeutics Casgevy for sickle cell disease/beta-thalassemia, the first approved CRISPR therapy) demonstrated commercial proof for ex vivo editing. Base editing (Verve, Beam Therapeutics) and prime editing (Prime Medicine) extend precision to single-base changes without double-strand breaks. Recombinase-based and large-payload integration is the emerging frontier where Profluent competes alongside Lilly's January 2026 collaboration with Seamless Therapeutics ($1.12B for hearing-loss recombinases) and Tessera Therapeutics' RNA-templated gene writing platform. Profluent differentiates through generative AI design of custom recombinases for arbitrary genomic targets, supported by its OpenCRISPR-1 demonstration of de novo enzyme design. Five-to-ten years post-close, Lilly's success will hinge on whether at least one Profluent-designed recombinase reaches IND, demonstrates durable in vivo gene insertion, and unlocks a previously intractable monogenic indication; the dual Seamless plus Profluent bet positions Lilly as the most aggressive large-pharma player in next-generation gene editing.